Published on

Toxicology – Thioridazine


Core Concept

Thioridazine is a phenothiazine first-generation antipsychotic with unusually important cardiac toxicity. In overdose it produces a combination of CNS depression, antimuscarinic effects, α₁-adrenergic blockade, cardiac sodium-channel blockade, and potassium-channel blockade with QT prolongation.

The major toxicologic sequence is:

Thioridazine → CNS/antimuscarinic effects + α-blockade + Na⁺-channel blockade + hERG/K⁺-channel blockade → sedation + hypotension + QRS widening + QT prolongation → ventricular dysrhythmia/TdP

The single most important modern distinction is:

QRS widening and QT prolongation are different toxic mechanisms and require different treatment.

QRS widening from sodium-channel blockade → sodium bicarbonate.

Long-QT torsades de pointes → magnesium + electrolyte correction ± defibrillation/overdrive pacing.

Giving therapies without distinguishing these mechanisms can worsen toxicity.


Current Status and Use

Thioridazine is not simply an obsolete withdrawn drug. Generic thioridazine tablets remain listed as prescription products in current U.S. DailyMed labeling in 2026. However, because of its dose-related QT prolongation and risk of torsades de pointes and sudden death, its use is extremely restricted compared with historical practice.

Current U.S. labeling reserves thioridazine for patients with schizophrenia who have failed adequate treatment with at least two other antipsychotic drugs because of either inadequate response or intolerable adverse effects.

Thus:

Thioridazine is still available, but it is a last-line antipsychotic because of proarrhythmic toxicity.


Mellaril

Mellaril is the historical brand name most strongly associated with thioridazine.

Current U.S. products are predominantly generic thioridazine rather than the historical brand.


Mesoridazine

Mesoridazine is both an active metabolite of thioridazine and a drug that was formerly marketed independently as Serentil.

Thioridazine undergoes S-oxidation to the active metabolites mesoridazine and sulforidazine. Mesoridazine itself prolongs the QT interval and blocks hERG potassium channels.

Serentil products are now on the FDA discontinued drug-product list. FDA subsequently determined that the products were not withdrawn for reasons of safety or effectiveness, meaning the regulatory status should not be interpreted as proof that mesoridazine was removed specifically because it was unsafe.

For modern toxicology practice, however, clinically encountered exposures are far more likely to involve thioridazine itself.


Current Therapeutic Dosing

Current U.S. labeling lists an adult starting dose of approximately:

50–100 mg orally three times daily

with gradual titration when required. Total adult dosage may range from 200–800 mg/day, divided into two to four doses.

Current tablets are available in 10-, 25-, 50-, and 100-mg strengths.

The modern importance of these numbers is mainly toxicologic, because thioridazine is now rarely selected when safer antipsychotics are available.


Pediatric Use

Current labeling still contains pediatric dosing for schizophrenia that has failed other agents, beginning around 0.5 mg/kg/day and increasing if required to a maximum of approximately 3 mg/kg/day.

In practical modern psychiatry, pediatric thioridazine use is uncommon because of the cardiac safety profile.


No Current Sustained-Release Formulation

The historical chapter repeatedly warns about “sustained-release thioridazine.”

That should not be carried forward as a major modern issue.

Current U.S. thioridazine products are conventional film-coated oral tablets, and current labeling does not describe a sustained-release thioridazine preparation.

Therefore:

Delayed cardiotoxicity is important because of the drug and its active metabolites—not because modern thioridazine is routinely an extended-release product.


Pathophysiology

Thioridazine has several clinically important pharmacologic actions.

It blocks dopamine D₂ receptors, explaining its antipsychotic effect and its potential for extrapyramidal effects, hyperprolactinemia, tardive dyskinesia, and neuroleptic malignant syndrome.

It also has substantial muscarinic antagonism, producing dry mouth, mydriasis, constipation, ileus, urinary retention, tachycardia, and delirium.

α₁-adrenergic blockade produces vasodilation and hypotension.

Most importantly in overdose, thioridazine can affect cardiac sodium and potassium currents, leading to conduction slowing and delayed repolarization.


Cardiac Potassium-Channel Blockade

Thioridazine and mesoridazine interfere with cardiac potassium currents, including hERG/IKr-mediated repolarization.

The result is:

K⁺-channel blockade → delayed ventricular repolarization → QT prolongation → early afterdepolarizations → torsades de pointes

QT prolongation is strongly dose related. Even therapeutic use is associated with enough QT risk that current labeling carries a boxed warning.


Cardiac Sodium-Channel Blockade

At high concentrations, thioridazine can also impair fast myocardial sodium channels.

The result is:

Na⁺-channel blockade → slowed phase-0 depolarization → intraventricular conduction delay → QRS widening → ventricular dysrhythmia + myocardial depression

This resembles the cardiotoxic physiology of tricyclic antidepressant poisoning.

The distinction from QT prolongation is essential because sodium bicarbonate treats sodium-channel blockade but does not directly treat torsades from potassium-channel blockade.


α-Adrenergic Blockade

Thioridazine’s potent peripheral α₁ blockade can produce substantial vasodilatory hypotension.

This has an important therapeutic consequence:

Epinephrine can cause paradoxical worsening of hypotension—the classic “epinephrine reversal” phenomenon.

Current labeling recommends predominantly α-active vasopressors such as norepinephrine or phenylephrine rather than epinephrine or dopamine for refractory phenothiazine-associated hypotension.


CYP2D6 and Toxicity

Thioridazine metabolism is strongly influenced by CYP2D6.

Reduced CYP2D6 activity can markedly increase thioridazine exposure. In a pharmacokinetic study, CYP2D6 poor metabolizers had approximately 2.4-fold higher peak concentrations and 4.5-fold greater overall exposure than rapid metabolizers.

This is clinically important because increased concentrations increase QT prolongation and arrhythmic risk.


Important Drug Interactions

Strong or clinically important CYP2D6 interactions can substantially increase thioridazine concentrations.

Current labeling specifically contraindicates or warns against combinations including:

Fluoxetine, paroxetine, fluvoxamine, propranolol, and pindolol.

Fluvoxamine has produced approximately a threefold increase in thioridazine and active-metabolite concentrations, while propranolol has produced very large increases in thioridazine and metabolite exposure.


QT-Prolonging Drug Interactions

Thioridazine should not be combined with other drugs that significantly prolong QT because effects can be additive.

Examples of clinically relevant QT-prolonging exposures include certain:

  • Antiarrhythmics
  • Antipsychotics
  • Macrolides
  • Fluoroquinolones
  • Methadone
  • Antiemetics
  • Other QT-active medications

Current labeling contraindicates thioridazine with other QT-prolonging drugs.


Risk Factors for Torsades

Important risk factors include:

Hypokalemia, hypomagnesemia, bradycardia, congenital long-QT syndrome, structural cardiac disease, CYP2D6 inhibition/poor metabolism, and coadministration of another QT-prolonging drug.

Current labeling specifically highlights bradycardia, hypokalemia, QT-prolonging co-medications, congenital long QT, and reduced CYP2D6 activity as major risk factors.


Therapeutic ECG Safety

Current labeling recommends obtaining a baseline ECG and serum potassium before therapeutic thioridazine use.

Patients with a baseline QTc >450 ms should not receive thioridazine, and treatment should be discontinued when QTc exceeds approximately 500 ms.

These therapeutic thresholds are useful for appreciating the drug’s unusually high intrinsic cardiac risk, but overdose treatment should be based on the entire ECG and clinical condition rather than one QT number.


Toxic Dose

There is no reliable single lethal-dose threshold.

Historical experience suggests that multi-gram ingestions can be life-threatening, but exact outcome cannot be predicted from dose alone.

A review of 223 acute overdoses found ventricular dysrhythmias primarily after large ingestions. Isolated ventricular arrhythmias occurred at a median reported dose around 12 g, while lower-dose cases with ventricular arrhythmia frequently had accompanying conduction abnormalities.

Therefore:

“A few grams can be lethal” is historically reasonable, but no milligram cutoff reliably predicts safety or death.


Clinical Features

The dominant acute syndrome is:

CNS depression + antimuscarinic findings + hypotension + cardiac conduction/repolarization toxicity

Severe poisoning may cause:

  • Coma
  • Respiratory depression
  • Seizures
  • QRS widening
  • QT prolongation
  • AV block
  • Ventricular tachycardia
  • Torsades de pointes
  • Ventricular fibrillation
  • Shock

Current labeling emphasizes cardiac toxicity as the principal major concern in overdose.


CNS Depression

Drowsiness and impaired consciousness are common.

The severity of altered consciousness generally increases with dose, and profound coma can produce airway obstruction, hypoventilation, and aspiration.

Historical overdose data found impairment of consciousness to be the most frequent clinical manifestation.


Antimuscarinic Findings

Thioridazine can produce:

Dry mouth + mydriasis + blurred vision + tachycardia + dry skin + urinary retention + constipation/ileus + delirium

Current overdose labeling describes both mydriasis and occasionally miosis, as well as dry skin, dry mouth, urinary retention, and blurred vision.


Hypotension

Hypotension can result from:

α₁ blockade + myocardial depression + dysrhythmia + dehydration

Severe hypotension can further increase the risk of cardiac dysrhythmia and cerebral or myocardial hypoperfusion.


QT Prolongation

QT prolongation may occur after therapeutic use and is especially concerning following overdose.

A 2025 systematic review of antipsychotic poisoning specifically identified thioridazine as one of the antipsychotics for which QT prolongation and torsades risk remain clinically important, and recommended cardiac monitoring in at-risk thioridazine overdoses.


Torsades de Pointes

Thioridazine can cause drug-induced long-QT torsades de pointes, which is a polymorphic ventricular tachycardia associated with delayed repolarization.

Although torsades was uncommon in historical overdose series, the drug’s mechanistic and therapeutic association with torsades and sudden death is sufficiently strong that it carries a boxed warning.


QRS Widening

Significant overdose can also produce intraventricular conduction slowing from sodium-channel blockade.

This may manifest as:

  • Broad QRS
  • Bundle-branch-like morphology
  • AV conduction abnormalities
  • Ventricular dysrhythmia
  • Hypotension

A widened QRS should not simply be called “QT toxicity.”


Bradycardia and AV Block

Severe poisoning may cause:

Bradycardia + PR prolongation + AV block

These may reflect direct conduction toxicity, severe myocardial dysfunction, hypoxia, or preceding dysrhythmia treatment.


Respiratory Toxicity

Severe overdose may produce respiratory depression, apnea, aspiration, or pulmonary edema.

Current labeling specifically lists respiratory depression, apnea, and pulmonary edema among overdose manifestations.

Respiratory compromise may also arise secondarily from prolonged seizures or shock.


Seizures

Seizures are uncommon in modest exposures but can develop in severe poisoning.

They increase:

  • Oxygen consumption
  • Acidosis
  • Hyperthermia
  • Rhabdomyolysis

Acidemia can further worsen sodium-channel-blocker cardiotoxicity, making rapid seizure control particularly important.


Extrapyramidal Effects

Acute dystonia, parkinsonian features, or other extrapyramidal symptoms can occur because of dopamine blockade.

Current labeling recommends treatment of acute extrapyramidal reactions with diphenhydramine or benztropine.


Tardive Dyskinesia

Tardive dyskinesia is primarily a chronic antipsychotic complication, not a characteristic acute-overdose syndrome.

Long-term dopamine blockade can produce involuntary oro-buccal-lingual and other choreoathetoid movements.


Neuroleptic Malignant Syndrome

NMS is another important antipsychotic complication, usually associated with therapeutic exposure, dose escalation, or other dopamine-blocking drugs rather than straightforward isolated acute overdose.

The classic syndrome is:

Hyperthermia + severe rigidity + altered mental status + autonomic instability

Current thioridazine labeling recognizes hyperpyrexia, rigidity, altered mental status, tachycardia, blood-pressure instability, diaphoresis, and dysrhythmia as characteristic NMS manifestations.


Pigmentary Retinopathy

Thioridazine has a distinctive chronic ocular toxicity.

High cumulative or excessive dosing can cause pigmentary retinopathy, with reduced visual acuity, impaired night vision, and altered color vision.

Current labeling notes that this complication occurs particularly with doses above recommended limits.

This is a chronic adverse effect rather than an acute-overdose marker.


Hematologic Toxicity

Leukopenia, neutropenia, and agranulocytosis are rare therapeutic adverse effects.

Current labeling recommends close CBC monitoring in patients with pre-existing low WBC counts or a history of drug-induced neutropenia and discontinuation if severe neutropenia develops.


Hepatic Toxicity

Phenothiazines can produce cholestatic or mixed hepatocellular/cholestatic liver injury.

This is more relevant to therapeutic adverse reactions than to the initial management of acute overdose.


Diagnosis

The diagnosis is usually based on:

Exposure history + clinical toxidrome + ECG

The most important investigation is an early 12-lead ECG, followed by serial ECGs and continuous cardiac monitoring after clinically significant overdose.


ECG Assessment

Assess:

Heart rate + rhythm + PR interval + QRS duration + QT/QTc + ectopy + AV conduction

Do not focus on QTc alone.

The ECG may demonstrate simultaneous:

  • QT prolongation
  • QRS widening
  • Bradycardia
  • AV block
  • Ventricular ectopy

Each has different implications.


QTc Interpretation

QTc interpretation becomes less reliable at extreme heart rates, so the morphology, absolute QT interval, rhythm, and clinical context matter.

In overdose, a markedly prolonged QT associated with ventricular ectopy or pause-dependent polymorphic VT is more concerning than a mildly elevated automated QTc value in isolation.


Electrolytes

Measure:

Potassium + magnesium + calcium

because hypokalemia and hypomagnesemia significantly increase torsades risk.

Correct these abnormalities aggressively but carefully.


Additional Laboratory Testing

In symptomatic or intentional overdose, useful tests include:

Glucose, electrolytes, bicarbonate, renal function, magnesium, calcium, CK, and blood gas when severe toxicity is present.

An acetaminophen concentration should be considered in intentional or uncertain multidrug ingestion.

CK should be measured after prolonged seizures, severe rigidity, hyperthermia, or prolonged immobilization.


Serum Thioridazine Levels

Serum thioridazine or mesoridazine concentrations are not useful for routine emergency management.

No rapidly actionable concentration threshold reliably predicts dysrhythmia or dictates treatment.

Management should be guided by:

ECG + blood pressure + mental status + clinical trajectory.


Initial Treatment

Initial priorities are:

Airway + ventilation + ECG monitoring + blood pressure support + electrolyte correction

Establish IV access and obtain an early ECG.

A significant overdose should be discussed with a poison center or medical toxicologist, particularly when QRS widening, marked QT prolongation, hypotension, seizure, or ventricular dysrhythmia is present.


Airway Management

Intubation is appropriate for:

  • Profound CNS depression
  • Loss of airway reflexes
  • Recurrent seizures
  • Severe hypoventilation
  • Aspiration
  • Respiratory failure

Correct hypoxia and acidemia rapidly because both can worsen cardiac instability.


Gastrointestinal Decontamination – Induced Emesis

Do not induce vomiting.

Ipecac is obsolete.

Thioridazine can cause abrupt CNS depression, dystonia, seizures, and dysrhythmia, making induced emesis particularly hazardous.


Gastric Lavage

The current thioridazine product label still contains historical overdose language suggesting gastric lavage.

That language does not reflect contemporary general toxicology practice.

AACT/EAPCCT guidance concludes that gastric lavage should not be performed routinely, if at all, because there is no convincing evidence of improved clinical outcome and significant complications can occur.

Therefore:

Routine gastric lavage is obsolete in thioridazine overdose.

Only an extraordinary, immediately life-threatening ingestion presenting very early could justify considering lavage after protected airway and expert toxicology consultation.


Activated Charcoal

A single dose of activated charcoal may be considered after a recent potentially toxic ingestion when the patient has an intact or protected airway.

AACT/EAPCCT guidance emphasizes that charcoal should not be routine, that benefit declines with time, and that the greatest potential benefit is generally within the first hour.

Thioridazine-associated CNS depression creates a substantial aspiration risk.

Thus:

Never give charcoal to a somnolent patient without airway protection.


Multiple-Dose Activated Charcoal

Historical/current labeling mentions repeated charcoal, but thioridazine is not one of the classic agents for which multiple-dose charcoal is established as an enhanced-elimination therapy.

Routine MDAC is therefore not recommended solely to increase thioridazine clearance.

An additional dose may occasionally be considered in a selected massive ingestion when tablets are thought to remain in the GI tract, but this should be toxicologist-directed. Contemporary recommendations increasingly distinguish additional-dose charcoal to prevent further absorption from true MDAC intended to enhance systemic elimination.


Antidote

There is no specific antidote for thioridazine poisoning.

Treatment is mechanism-based supportive toxicology.


QRS Widening – Sodium Bicarbonate

When significant QRS widening, ventricular dysrhythmia, shock, or other evidence of cardiac sodium-channel blockade is present:

Give hypertonic sodium bicarbonate.

A reasonable initial regimen is:

Sodium bicarbonate 1–2 mEq/kg IV bolus

with repeat dosing guided by improvement in QRS duration, hemodynamics, and rhythm.

A 2024 clinical toxicology review recommends 1–2 mmol/kg for clinically significant sodium-channel-blocker toxicity, with serial ECG, electrolytes, and blood-gas monitoring.


Sodium Bicarbonate Target

When repeated bicarbonate is required, a reasonable alkalinization goal is approximately:

pH 7.45–7.55

while avoiding severe alkalemia, hypernatremia, hypokalemia, and hypocalcemia.


Critical Bicarbonate Pitfall

Thioridazine is not a pure sodium-channel blocker.

It also markedly prolongs repolarization.

Excessive bicarbonate can produce hypokalemia, which can further prolong QT and increase torsades risk. Modern toxicology commentary specifically warns that aggressive bicarbonate can worsen QT-related toxicity in drugs affecting multiple cardiac channels.

Therefore:

Use bicarbonate for QRS/sodium-channel toxicity—not merely because the QT is long.

Follow potassium closely.


Long-QT Torsades de Pointes

For polymorphic VT occurring in the setting of a prolonged QT:

IV magnesium is first-line for recurrence prevention.

Correct:

  • Hypokalemia
  • Hypomagnesemia
  • Hypocalcemia when significant
  • Bradycardia/pause dependence

AHA guidance supports magnesium for recurrent polymorphic VT associated with long QT and recommends immediate unsynchronized shock for sustained polymorphic VT.


Magnesium

A commonly used adult regimen is:

Magnesium sulfate 2 g IV

for torsades, with additional dosing depending on clinical response and magnesium concentration.

Magnesium may be useful even if the measured serum magnesium level is normal because its anti-torsades action is electrophysiologic rather than simply replacement of deficiency.


Defibrillation

Sustained or hemodynamically unstable polymorphic VT should be defibrillated immediately.

Torsades can deteriorate rapidly into ventricular fibrillation.

Magnesium and correction of the underlying repolarization abnormality are then needed to prevent recurrence.


Overdrive Pacing

If recurrent torsades is associated with bradycardia or pauses, increasing the heart rate can suppress pause-dependent early afterdepolarizations.

AHA guidance supports specialist consideration of overdrive pacing in recurrent pause-dependent torsades.

This is particularly useful when magnesium and electrolyte correction are insufficient.


Isoproterenol

Isoproterenol can sometimes be used for recurrent pause-dependent acquired torsades when overdrive pacing is not immediately available.

However, in thioridazine poisoning it must be used cautiously because thioridazine also causes hypotension and complex adrenergic effects.

It should therefore be reserved for specialist-directed management of bradycardia-dependent torsades, not ordinary thioridazine-associated tachyarrhythmia.


Antiarrhythmics to Avoid

Avoid antiarrhythmics that further prolong QT, especially:

Procainamide, quinidine, disopyramide, sotalol

and generally avoid reflexive use of amiodarone in true drug-induced long-QT torsades, because further repolarization prolongation may worsen the problem.

Current thioridazine labeling specifically warns against procainamide, quinidine, and disopyramide because of additive QT prolongation.


Lidocaine

Lidocaine may be considered for selected ventricular dysrhythmias from sodium-channel-blocking toxicity, particularly when QRS widening is present and bicarbonate has not fully controlled the rhythm.

It should not be regarded as treatment for long-QT torsades.

The exact rhythm mechanism should be established before selecting an antiarrhythmic.


Hypotension

Give isotonic crystalloid when appropriate, particularly if the patient is volume depleted.

If significant hypotension persists:

Norepinephrine is a preferred vasopressor.

Phenylephrine is another reasonable option when pure vasoconstriction is desired.

Current labeling specifically identifies norepinephrine and phenylephrine as appropriate pressors for refractory thioridazine-associated hypotension.


Avoid Epinephrine in Phenothiazine Hypotension

Thioridazine blocks α receptors.

Epinephrine can therefore produce disproportionate β₂-mediated vasodilation after α blockade, causing paradoxical worsening of hypotension.

Thus:

Avoid epinephrine for routine thioridazine-induced vasodilatory shock when alternatives are available.

Current labeling explicitly warns about this reversed epinephrine effect.


Dopamine

The old dopamine-first vasopressor approach is outdated.

Current thioridazine labeling also cautions against dopamine because its mixed α/β effects may be unpredictable in the presence of potent phenothiazine α blockade.


Seizure Treatment

Benzodiazepines are first-line.

Use standard toxicologic seizure therapy with airway monitoring.

Refractory seizures can be treated with additional GABAergic therapy such as phenobarbital or propofol when airway support is available.

The older recommendation to add phenytoin should not be considered preferred modern toxicologic seizure therapy.


Acidemia

Correct hypoxia, ventilation, seizures, and shock.

Acidemia is particularly undesirable in sodium-channel-blocker poisoning because protonation and drug-channel interactions can worsen cardiotoxicity.

When QRS widening is present, sodium bicarbonate provides both sodium loading and alkalinization.


Acute Dystonia and Extrapyramidal Symptoms

Acute dystonic reactions may be treated with:

Diphenhydramine or benztropine

as recognized in current labeling.

Patients may need short continued treatment because symptoms can recur after the initial anticholinergic dose wears off.


Neuroleptic Malignant Syndrome

When NMS is suspected:

Stop thioridazine and all dopamine antagonists immediately.

Provide:

  • Aggressive cooling
  • IV fluids
  • Correction of electrolytes
  • Treatment of rhabdomyolysis
  • Renal monitoring
  • Respiratory/hemodynamic support

Benzodiazepines are often useful.

Dantrolene or dopamine agonists such as bromocriptine may be considered in selected severe cases, but supportive critical care remains the foundation.


Rhabdomyolysis

Rhabdomyolysis may occur after:

  • Seizures
  • NMS
  • Severe agitation
  • Hyperthermia
  • Prolonged immobilization

Monitor:
CK + potassium + creatinine + urine output

and manage using standard rhabdomyolysis principles.


Enhanced Elimination

Thioridazine has a large volume of distribution and extensive protein/tissue binding.

Therefore:

Hemodialysis does not meaningfully enhance thioridazine elimination.

Current labeling similarly states that hemodialysis, hemoperfusion, forced diuresis, and urine-pH manipulation are unlikely to be beneficial.


Intravenous Lipid Emulsion

IV lipid emulsion is not established routine treatment for thioridazine poisoning.

Because thioridazine is lipophilic, lipid rescue may be discussed in an exceptional refractory cardiovascular collapse after conventional therapy has failed, but evidence is insufficient for routine use.

Any such use should involve a medical toxicologist.


ECMO

For otherwise refractory cardiogenic shock or recurrent lethal dysrhythmia despite maximal conventional therapy, venoarterial ECMO may be considered as salvage support at an experienced center.

This is not a thioridazine-specific antidote but can provide temporary circulatory support while a reversible drug exposure clears. Modern AHA poisoning guidance recognizes VA-ECMO as a potential rescue therapy in selected refractory cardiotoxic poisonings.


Monitoring

Continuous cardiac monitoring is essential after a significant thioridazine overdose.

The 2025 Clinical Toxicology QT workgroup specifically recommends cardiac monitoring for at-risk thioridazine overdose because it is among the relatively small group of antipsychotics with meaningful QT/TdP risk.

Repeat ECGs should follow:

  • QRS duration
  • QT/QTc
  • Rhythm
  • AV conduction

Electrolytes should be rechecked during evolving toxicity and after bicarbonate therapy.


Delayed Cardiotoxicity

The older text correctly emphasized that dysrhythmia may be delayed.

Current labeling states that observation for several days may occasionally be required because delayed effects can occur.

Thus:

A normal ECG soon after a major ingestion does not automatically guarantee safety.

Observation should be individualized according to dose, symptoms, ECG evolution, coingestants, and time since ingestion.


Observation and Disposition

The old fixed 6–8 hour discharge rule should not be applied automatically to all exposures.

For a clearly minor ingestion in an asymptomatic patient with reassuring serial ECGs and poison-center assessment, discharge after an adequate observation period may be reasonable.

However, substantial or intentional thioridazine overdose deserves longer monitoring because of the drug’s specific delayed cardiac risk.


Admission

Hospital admission is appropriate for:

CNS depression, hypotension, QRS widening, QT prolongation, electrolyte abnormalities, seizures, significant antimuscarinic toxicity, or intentional substantial overdose.


ICU Admission

ICU-level management is warranted for:

Coma, respiratory failure, shock, seizures, QRS widening with instability, marked QT prolongation with ventricular ectopy, torsades, sustained ventricular dysrhythmia, high-grade AV block, severe hyperthermia, or NMS.


Discharge

Before discharge after significant poisoning, the patient should have:

  • Normal or baseline mental status
  • Stable blood pressure
  • No clinically important dysrhythmia
  • Reassuring QRS and QT trends
  • Corrected potassium and magnesium
  • No evolving delayed complication

Intentional overdose requires appropriate psychiatric and safety assessment.


Pregnancy

The historical FDA Pregnancy Category C system is obsolete.

Current labeling states that available experience has not established a clear teratogenic effect but recommends thioridazine during pregnancy only when potential benefit justifies risk.

Third-trimester exposure to antipsychotics can produce neonatal:

Agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding difficulty, and extrapyramidal/withdrawal symptoms.

In acute maternal overdose, maternal stabilization takes priority.


Breastfeeding

There is very little published lactation experience with thioridazine.

LactMed recommends that an alternative antipsychotic generally be preferred during breastfeeding, particularly for a newborn or premature infant, because infant exposure and effects have not been adequately studied.

Phenothiazines can also raise prolactin and cause galactorrhea.


Older Adults

Older patients are particularly vulnerable to:

  • Orthostatic hypotension
  • Antimuscarinic delirium
  • Falls
  • Cardiac conduction disease
  • Drug interactions

Thioridazine should also not be used for dementia-related psychosis. Current labeling carries the class boxed warning for increased mortality in elderly patients with dementia-related psychosis.


Important Pitfalls

The first major pitfall is assuming thioridazine is completely unavailable.

Generic thioridazine remains listed as a marketed U.S. prescription drug in 2026, although its use is highly restricted.


Another pitfall is treating QRS widening and QT prolongation as the same ECG abnormality.

They are not.

Wide QRS → think sodium-channel blockade → sodium bicarbonate.

Long QT + torsades → magnesium + K/Mg correction ± pacing/defibrillation.


Another pitfall is giving sodium bicarbonate simply because the QTc is long.

Excess bicarbonate can produce hypokalemia, worsening repolarization and potentially increasing torsades risk.


Do not use procainamide, quinidine, disopyramide, or other QT-prolonging antiarrhythmics for thioridazine-related ventricular instability. Current labeling specifically warns against additive QT effects.


Another important error is using epinephrine or dopamine reflexively for hypotension.

Because phenothiazines produce potent α blockade, paradoxical vasodilation can occur.

Prefer norepinephrine or phenylephrine.


Do not assume propranolol is a safe treatment for thioridazine-associated tachycardia. Propranolol substantially increases thioridazine and metabolite concentrations and is specifically contraindicated with therapeutic thioridazine.


Do not miss CYP2D6 interactions. Fluoxetine, paroxetine, fluvoxamine and other interacting drugs can markedly increase exposure and QT risk.


Do not use serum thioridazine levels to guide emergency therapy.

The ECG is the useful “drug level.”


The old recommendation for routine gastric lavage should not be followed. Modern AACT/EAPCCT guidance advises that lavage should not be performed routinely, if at all.


Activated charcoal is selective rather than automatic and requires an intact or protected airway.


Do not initiate dialysis to clear thioridazine.

It has a large volume of distribution and substantial protein/tissue binding, making hemodialysis and hemoperfusion ineffective for toxin removal.


The old warning regarding “sustained-release thioridazine” is not a major contemporary issue because current U.S. thioridazine products are conventional tablets. Delayed toxicity remains possible because of the drug’s pharmacology and active metabolites.


High-Yield Toxicology Pearls

Thioridazine is one of the antipsychotics in which cardiac toxicity genuinely matters.

The 2025 Clinical Toxicology QT workgroup specifically identifies thioridazine as an antipsychotic warranting cardiac monitoring after at-risk overdose.


The core overdose syndrome is:

Sedation + antimuscarinic effects + hypotension + QRS widening + QT prolongation


Thioridazine has at least four important mechanisms:

D₂ blockade → extrapyramidal/NMS effects

Muscarinic blockade → anticholinergic syndrome

α₁ blockade → hypotension

Cardiac Na⁺/K⁺ channel effects → QRS widening + QT prolongation


QRS widening ≠ QT prolongation.

For clinically significant sodium-channel blockade:

Sodium bicarbonate 1–2 mEq/kg IV

with repeat dosing based on ECG and hemodynamic response and careful monitoring of pH, potassium, sodium, and calcium.


For drug-induced long-QT torsades:

Magnesium sulfate + correction of K⁺/Mg²⁺ + immediate defibrillation if sustained/unstable

and consider overdrive pacing for recurrent pause-dependent torsades.


Avoid QT-prolonging antiarrhythmics such as procainamide, quinidine, and disopyramide.


For refractory hypotension:

Norepinephrine or phenylephrine

is preferred.

Avoid routine epinephrine because α blockade can produce epinephrine reversal and paradoxical worsening of hypotension.


Treat seizures with benzodiazepines first-line.

Treat acute dystonia with diphenhydramine or benztropine.


There is:

No specific antidote.

Hemodialysis and hemoperfusion do not meaningfully enhance elimination.


Routine gastric lavage and induced emesis are obsolete. A single dose of activated charcoal can be considered early after a significant ingestion when the airway is safe.


Thioridazine is metabolized through CYP2D6, and poor metabolizers or patients taking CYP2D6 inhibitors can develop substantially higher concentrations and greater QT risk.


Current therapy is restricted to treatment-refractory schizophrenia after adequate trials of other antipsychotic agents because of potentially fatal proarrhythmic effects.


Mesoridazine is an active thioridazine metabolite and also prolongs QT. Its former U.S. product Serentil is discontinued, while generic thioridazine itself remains available.


The most important bedside warning is:

In thioridazine poisoning, look at both the QRS and the QT—one tells you when to give bicarbonate, the other tells you when to fear torsades.



Image description
0 Comments